Driss Fantini
CEO
AmyPore
AmyPore is developing a therapeutic agent that targets tau protein aggregation, a key mechanism in the neurodegeneration associated with Alzheimer's and Parkinson's diseases. This approach aims to enhance cognitive function and slow disease progression in affected patients.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$820KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Jacques Fantini
President
Product
Problem
Alzheimer's and Parkinson's diseases are characterized by the aggregation of specific proteins (Aβ for Alzheimer's, α-syn for Parkinson's) in the brain, leading to neurodegeneration. Among the different forms of aggregation, soluble oligomers are the most neurotoxic, appearing early in the pathogenesis and causing significant neuronal damage. These oligomers form amyloid pores in neuronal membranes, disrupting calcium ion (Ca2+) homeostasis and triggering a cascade of neurotoxic events.
Solution
AmyPore is developing AmyP53, a therapeutic peptide designed to target and neutralize neurotoxic amyloid oligomers implicated in Alzheimer's and Parkinson's diseases. Using molecular modeling applied to neurosciences, AmyPore has designed AmyP53 to bind to gangliosides, preventing the formation of amyloid pores and the subsequent influx of calcium ions into brain cells. This mechanism aims to halt the neurotoxic cascade, reduce oxidative stress, prevent tau protein hyperphosphorylation, and restore synaptic function. AmyP53 represents a novel therapeutic approach with the potential for non-invasive administration via nasal spray.
Target Audience
The primary target audience includes individuals at risk of or affected by Alzheimer's and Parkinson's diseases, as well as pharmaceutical companies and research institutions focused on neurodegenerative disorders.
Features
- Therapeutic peptide (AmyP53) designed using molecular modeling techniques.
- Targets amyloid oligomers, the most neurotoxic form of protein aggregates in Alzheimer's and Parkinson's diseases.
- Prevents the formation of amyloid pores in neuronal and astrocyte membranes.
- Blocks calcium ion influx, mitigating downstream neurotoxic effects.
- Designed for non-invasive administration via nasal spray.